Cancer Drug News Issue 666

Description: The favourable terms for academia in the deal highlight a shift in dynamics in industry-academia partnership. As more big pharma companies seek to leverage open innovation to drive lower cost, faster and more flexible R&D, competition for top institutions will increase. We expect a move away from academia being seen as just a provider of early research for the industry, towards more equally weighted partnerships.

Contents:
1 Dynamics Within Industry-Academia Partnerships Changing
   - Haematological Cancer
2 CHMP Adopts Positive Opinion On Empliciti For MM
3 Kyprolis Approved For Multiple Myeloma In Canada
4 Bendeka Available In US
3 Venetoclax Receives FDA Breakthrough Therapy Designation For AML
   - Genito-Urinary Cancer
4 Cabozantinib Will Encounter Toughening Market Environment Despite Swift Entry
5 Tookad Filed For Approval In Mexico Following Positive Phase III Results In PCA
6 AstraZeneca's Lynparza Drive Will Secure Sustained Revenue Growth
7 Stelba Submits Tookad MAA To EMA
   - Gastrointestinal Cancer
8 Caboza Phase II Substudy Stopped Early Due To Insufficient Efficacy
7 Halozyme Raises Funds To Continue Oncology Development
   - General Developments
8 Sun Launches Imatinib Mesylate In US
8 HUYA Grants Exclusive Licence For HBI-8000 To Eisai
8 Aduro Receives Clinical Development Milestone Payments From Janssen
8 FDA Approves Eisai's Halaven For Advanced Liposarcoma
9 Adicet Raises Funds; Acquires Applied Immune Technologies
   - Supportive Therapies
9 Spectrum Initiates SPI-2012 Phase III Trial Chemotherapy-Induced Neutropenia In BC
   Corporate Activity
9 Strong Oncology Profile To Support 2016 Growth


Order by Fax - using the form below

Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct.

Product Name: Cancer Drug News Issue 666
Web Address: http://www.researchandmarkets.com/reports/3758123/
Office Code: SCD22DYS

Product Format
Please select the product format and quantity you require:

Quantity
Electronic (PDF) - Single User: [ ] USD 1252

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: [ ] Mr [ ] Mrs [ ] Dr [ ] Miss [ ] Ms [ ] Prof
First Name: ____________________________ Last Name: ____________________________
Email Address: * ____________________________
Job Title: ____________________________
Organisation: ____________________________
Address: ____________________________
City: ____________________________
Postal / Zip Code: ____________________________
Country: ____________________________
Phone Number: ____________________________
Fax Number: ____________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:

- **Account number**: 833 130 83
- **Sort code**: 98-53-30
- **Swift code**: ULSBIE2D
- **IBAN number**: IE78ULSB98533083313083
- **Bank Address**: Ulster Bank,
  27-35 Main Street,
  Blackrock,
  Co. Dublin,
  Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: __________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:

(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World